Nov 7, 2026
Péptidos Verificados brings the full catalog together for online purchase, while Péptido Retatrutida focuses on a molecule as it rounds out its Phase 3 program.
Mexico City, Mexico, November 7, 2026 -- Mexico City, Mexico, 7th November – Certified PEP MEX is a research peptide company that supplies research-use-only (RUO) compounds, and today it announced it is expanding its reach in Mexico with two new websites: Péptidos Verificados at https://peptidosverificados.mx/, where every item in the catalog is available for purchase, and Péptido Retatrutida at https://peptido-retatrutida.mx/, which focuses specifically on retatrutide.
The announcement comes as interest in research peptides continues to grow in the country. Péptidos Verificados brings together 39 compounds in 48 presentations, each with a batch-specific certificate of analysis (COA) and FedEx shipping across Mexico from the official store at https://certified-peptidos.mx/. Péptido Retatrutida offers detailed information on the triple-receptor molecule just as its clinical development approaches a key regulatory stage.

“More and more researchers in Mexico are looking for peptides with documentation they can verify for themselves, and we wanted to give them one clear site with the full catalog and another dedicated to retatrutide as it rounds Phase 3,” said Benson Jamison of Certified PEP. “Every vial carries a QR code that opens the lab report for its batch.”
What Each Site Offers
Prices and availability may change without notice.
Retatrutide: Phase 3 Enters the Home Stretch
On July 23, 2026, Eli Lilly announced positive results from the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, bringing the total to five positive Phase 3 studies for retatrutide. The company plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027.
Retatrutide remains an investigational compound and is not approved as a medicine by the FDA or COFEPRIS. The material offered by Certified PEP MEX is a research-grade compound, distinct from the pharmaceutical product used in clinical trials, and is sold strictly for laboratory use. None of the clinical results mentioned constitute claims about Certified PEP MEX products.
Quality and Transparency
Certified PEP MEX peptides are manufactured in the United States in a cGMP-compliant facility and tested by independent laboratories, most often Vanguard Laboratory in Olympia, Washington, which is accredited under ISO/IEC 17025:2017. Every batch has its own COA, and the QR code on each vial opens the report directly on the testing laboratory’s own website.
Research Use Only: Certified PEP MEX products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use, consumption, clinical use, diagnosis, treatment or prevention of disease. No dosing or administration information is provided. Statements in this release have not been evaluated by the U.S. Food and Drug Administration or by COFEPRIS in Mexico.
About Certified PEP MEX
Certified PEP MEX supplies peptides and compounds for qualified laboratory research in Mexico. The company emphasizes U.S. manufacturing, batch-specific independent testing, product labeling with COA information, transparent documentation and customer support in Mexico. Certified PEP MEX products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use or clinical applications.
Contact Info:
Name: Benson Jamison
Email: Send Email
Organization: Certified PEP MEX
Phone: 52 55 8526 4324
Website: https://certified-peptidos.mx/
Release ID: 89208820
In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.
Is the company dead? Will everything be on sale? And can shoppers still redeem gift cards at the department store stalwart?
Small businesses that supply the department store will take a financial hammering from the company’s dramatic collapse.
It’s no secret that schools, to a great extent, run on the goodwill of staff. But this is taking it too far.
Network Ten insists its cost-cutting drive is not a redundancy round. But it sounds a lot like one.
Billionaire Paul Little is having another stab at selling a development site overlooking prestigious Melbourne High School’s hockey pitch.
Both the Reserve Bank and government are copping blame for things out of their control. But bending to pressure might put us in a worse position.
Sydney’s T2 domestic terminal will soon offer lounge access to departing passengers regardless of airline, ticket class or frequent flyer status.
As results began to pour in on a bruising midterm election night for the Republicans, Trump picked an unlikely scapegoat.
The Australian sharemarket soared the most since April as the Democrats’ sweeping US election victory fuelled optimism the Iran war could end soon, sending oil prices plunging.
Kuniko has struck gold-silver mineralisation in all 11 drill holes across two campaigns at its NSW Commonwealth-Silica Hill project ahead of a December resource update.
ClearVue and US partner Silfab Solar have won a US$500,000 grant from the US Dept of Energy to develop high-efficiency solar spandrel technology for the US market.
David Jones’ owners have appointed administrators, which is expected to trigger an extensive restructure of the company and thousands of job losses.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.